share_log

Zhe Jiang Dayang Biotech Group's (SZSE:003017) Soft Earnings Are Actually Better Than They Appear

Zhe Jiang Dayang Biotech Group's (SZSE:003017) Soft Earnings Are Actually Better Than They Appear

這江大洋生物科技集團(SZSE:003017)的軟收益實際上比表面上看起來要好
Simply Wall St ·  2024/10/25 15:32

Soft earnings didn't appear to concern Zhe Jiang Dayang Biotech Group Co., Ltd.'s (SZSE:003017) shareholders over the last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

上週,淡江大洋生物科技股份有限公司(SZSE:003017)的股東似乎並未對較弱的收益表示擔憂。我們認爲,較弱的主要數字可能正被一些積極的基本因素所抵消。

big
SZSE:003017 Earnings and Revenue History October 25th 2024
SZSE:003017每股收益和營業收入歷史數據:2024年10月25日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Zhe Jiang Dayang Biotech Group's profit was reduced by CN¥13m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Zhe Jiang Dayang Biotech Group to produce a higher profit next year, all else being equal.

重要的是,我們的數據顯示,由於飛凡項目,淡江大洋生物科技集團去年的利潤減少了1300萬元人民幣。看到飛凡項目影響公司利潤並不是件好事,但從積極的一面來看,情況可能會比想象中更快地好轉。我們查看了成千上萬家上市公司,發現飛凡項目很常見,並通常是一次性的。畢竟,這正是會計術語的意義所在。假設這些飛凡開支不再出現,我們因此預計,其他條件不變的情況下,淡江大洋生物科技集團明年將產生更高的利潤。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Zhe Jiang Dayang Biotech Group.

注:我們始終建議投資者檢查資產負債表的強度。 點擊這裏查看我們對淡江大洋生物科技集團資產負債表分析。

Our Take On Zhe Jiang Dayang Biotech Group's Profit Performance

我們對淡江大洋生物科技集團的利潤表現看法

Because unusual items detracted from Zhe Jiang Dayang Biotech Group's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Zhe Jiang Dayang Biotech Group's earnings potential is at least as good as it seems, and maybe even better! On the other hand, its EPS actually shrunk in the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Zhe Jiang Dayang Biotech Group, you'd also look into what risks it is currently facing. While conducting our analysis, we found that Zhe Jiang Dayang Biotech Group has 1 warning sign and it would be unwise to ignore this.

由於飛凡項目在過去一年中影響了浙江大洋生物科技集團的收益,因此我們可以認爲我們可以期待本季度有所改善。由於這個原因,我們認爲浙江大洋生物科技集團的收益潛力至少和看上去一樣好,甚至可能更好!另一方面,在過去十二個月中,其每股收益實際上有所縮水。本文的目標是評估我們可以依靠法定收益來反映公司潛力的程度,但還有很多需要考慮的因素。如果您想更深入地了解浙江大洋生物科技集團,您還應該研究一下它目前面臨的風險。在進行分析時,我們發現浙江大洋生物科技集團有一個警示信號,忽視這一點是不明智的。

This note has only looked at a single factor that sheds light on the nature of Zhe Jiang Dayang Biotech Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這個說明只看了浙江大洋生物科技集團利潤性質的一個因素。但是,如果你有能力集中精力研究細枝末節,你會發現更多有趣的事情。例如,許多人認爲高股本回報率是有利的商業經濟狀況的一個指標,而其他人則喜歡「追隨資金」並尋找公司內部人員正在買入的股票。雖然這可能需要您進行一些研究,但您可能會發現這個免費的公司收藏中有許多股本回報率高的公司,或者這個擁有大量內部持股的股票清單是有用的。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論